R. Malé-Velazquez

The second Mexican consensus on hepatocellular carcinoma. Part II: Treatment.

N. Méndez-Sánchez, M. Vilatoba, E. Cerda-Reyes, 2022, Revista de gastroenterologia de Mexico.

Re-treatment with highly purified nIFNα in Mexican nonresponder patients with chronic genotype 1 hepatitis C.

L. Muñoz-Espinosa, P. Cordero-Pérez, L. Torres-González, 2013, Archives of medical research.

The Mexican consensus on the treatment of hepatitis C

D. Kershenobich-Stalnikowitz, N. Chavez-Tapia, L. Muñoz-Espinosa, 2018, Revista de Gastroenterología de México (English Edition).

The Mexican consensus on the treatment of hepatitis C.

D. Kershenobich-Stalnikowitz, N. Chavez-Tapia, L. Muñoz-Espinosa, 2018, Revista de gastroenterologia de Mexico.

POSITION STATEMENT ON THE USE OF ALBUMIN IN LIVER CIRRHOSIS.

G. Castro-Narro, E. Cerda-Reyes, R. Contreras-Omaña, 2022, Annals of hepatology.

Mexican consensus on the diagnosis and management of hepatitis C infection.

R. Vázquez-Frias, N. Méndez-Sánchez, F. Bosques-Padilla, 2015, Annals of hepatology.

The Mexican consensus on nonalcoholic fatty liver disease

C. Aguilar-Salinas, D. Kershenobich-Stalnikowitz, N. Chavez-Tapia, 2019, Revista de Gastroenterología de México (English Edition).

The Mexican consensus on nonalcoholic fatty liver disease

C. Aguilar-Salinas, D. Kershenobich-Stalnikowitz, N. Chavez-Tapia, 2019, Revista de Gastroenterología de México (English Edition).

End-stage renal disease and hepatitis C infection: comparison of alanine aminotransferase levels and liver histology in patients with and without renal damage.

G. Vázquez, A. Celis, I. Ruiz, 2007, Annals of hepatology.

The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis.

N. Méndez-Sánchez, M. Vilatoba, E. Cerda-Reyes, 2022, Revista de gastroenterologia de Mexico.